Prescribing Information Visit Patient website

Comprehensive support to help your patients start their prescribed therapy

How to get started with LYNAVOY

  • Send the LYNAVOY prescriptions directly to PANTHERx Rare Pharmacy, our specialty pharmacy partner
  • Enroll patients in Interconnect for additional access and support offerings

PANTHERx Rare Pharmacy

PANTHERx provides dispensing, clinical support, and access coordination through its RareCARE team, including PA support, appeals, and fulfillment.

pantherxrare.com
Fax: 1-877-912-0734
Phone: 1-866-347-0951

Interconnect® Support Services

Interconnect provides patient support and access to financial assistance programs.

interconnectsupport.com
Fax: 1-833-636-1742
Phone: 1-844-622-4278

*Offer not valid for patients enrolled in Medicare, DoD, VA, Medicaid, or other federal or state healthcare programs. For program terms, conditions, and eligibility criteria, visit www.interconnectsupport.com

PA=Prior Authorization.

Our goal is to make prescribing LYNAVOY seamless so you can focus on patient care

PDF resources for you and your patients

“How to Start LYNAVOY” brochure will provide you with important information for prescribing LYNAVOY.

Download the “Doctor/Patient Dialogue Tool,” which will help you have a better discussion with your PBC patients about their itch, and the impact it may have on their lives.

Important Safety Information

Warnings and Precautions

Liver Test Elevations were observed more commonly in LYNAVOY-treated patients compared to placebo-treated patients.

  • Obtain baseline liver tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin [TB], direct bilirubin [DB], alkaline phosphatase [ALP]) prior to initiating treatment with LYNAVOY and monitor the levels per standard clinical practice for PBC patients during treatment with LYNAVOY.
  • If new liver test elevations occur, monitor ALT, AST, TB, DB, and ALP more frequently.
  • If liver test elevations persist, discontinue LYNAVOY.

Diarrhea was reported as the most common adverse reaction in patients treated with LYNAVOY.

  • If diarrhea occurs, advise patients to monitor for dehydration.
  • Consider interrupting or discontinuing LYNAVOY treatment if diarrhea persists.

Fat-Soluble Vitamin (FSV) Deficiency: LYNAVOY may adversely affect absorption of FSV (i.e., vitamins A, D, E, and K).

  • Obtain serum levels for vitamins A, D, and E and INR prior to initiation of LYNAVOY.
  • Monitor the levels periodically during treatment, along with any clinical manifestations of FSV deficiency.
  • Supplement with FSV if a deficiency is diagnosed.
  • Consider discontinuing LYNAVOY if FSV deficiency persists or worsens despite adequate supplementation.
  • Bleeding was observed more frequently in LYNAVOY-treated patients compared to placebo-treated patients.
    • If bleeding occurs, interrupt LYNAVOY treatment and evaluate for potential FSV deficiency.
    • LYNAVOY can be restarted if FSV deficiency is corrected, levels are maintained, and bleeding has resolved.
  • Bone Fracture has been associated with IBAT inhibitors.
    • Monitor bone health and ensure adequate FSV levels.

Adverse Reactions

The most common adverse reactions (≥5%) are diarrhea, abdominal pain, nausea, increased ALT, hemorrhage, increased AST, headache, dyspepsia, gastroesophageal reflux disease, abdominal distension, dizziness, and arthralgia.

Drug Interactions

  • Effect of Bile Acid Binding Resins on LYNAVOY: Administer at least 4 hours before or 4 hours after administration of LYNAVOY.

To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals 1-844-782-4278 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see the full Prescribing Information for LYNAVOY.

Indication:

LYNAVOY (linerixibat) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients.

Limitations of Use: Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g. variceal hemorrhage, ascites, hepatic encephalopathy).

References

  1. 1. LYNAVOY (linerixibat) Prescribing Information. Morristown, NJ: Intercept Pharmaceuticals.
  2. 2. Alfasigma. Linerixibat approved for use in the U.S. for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC). Press release. March 19, 2026. Accessed October 6, 2026. https://alfasigma.com/news-media/linerixibat-approved-for-use-in-the-u-s-for-the-treatment-of-cholestatic-pruritus-in-primary-biliary-cholangitis-pbc
  3. 3. Kode V, Yimam KK. Cholestatic pruritus: pathophysiology, current management approach, and emerging therapies. Current Hepatology Reports. 2024;23(1):123-136. doi:10.1007/s11901-024-00638-7
  4. 4. Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389(10074):1114-1123. doi:10.1016/S0140-6736(17)30319-7
  5. 5. Naumann S, Haller D, Eisner P, Schweiggert-Weisz U. Mechanisms of interactions between bile acids and plant compounds-a review. Int J Mol Sci. 2020;21(18):6495. doi:10.3390/ijms21186495
  6. 6. Food and Drug Administration. LYNAVOY (linerixibat) NDA 220295: Integrated Review. Published 2026. Accessed August 4, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220295Orig1s000IntegratedR.pdf
  7. 7. Hirschfield GM, Bowlus CL, Jones DEJ, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22-33. doi:10.1016/S2468-1253(25)00192-X
  8. 8. Bowlus L. Long-term safety, tolerability and maintenance of efficacy of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: An interim analysis. Poster presented at: EASL 2026; May 27-30, 2026; Barcelona, Spain.
  9. 9. Bowlus CL, Gordon SC, Jones DE, et al. TOP-280: Long-term safety, tolerability and maintenance of efficacy of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis. J Hepatol. 2026;84(suppl 1):S295-S296. doi:10.1016/ S0168-8278(26/00974-8
  10. 10. Hirschfield GM. Supplement to: Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22-33. doi:10.1016/S2468-1253(25/00192-X